We continue our analytics coverage of AstraZeneca PLC with a "hold" rating for the next 12 months. AstraZeneca's revenue for the first three months of 2023 was $10.88 billion, down 2.9% from the ...

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "Our strong growth momentum has continued into 2025 and we have now entered an unprecedented catalyst-rich period for our company. Already ...

AstraZeneca, the global pharmaceutical group with key North West interests, reported better annual revenues and a steep increase in pre-tax profits in its 2025 financial year. Total revenues of ...

AstraZeneca (AZN) shares added ~2% in the premarket on Tuesday after the Anglo-Swedish drugmaker exceeded Street forecasts with its Q4 2025 financials, thanks mainly to its oncology portfolio. The U.K ...

AstraZeneca’s CEO, a French-born Australian running an Anglo-Swedish company, is betting $50 billion on a strategy of making the US its largest market — while also pouring $15 billion into China. Each ...

Both AstraZeneca and Roche lifted their respective full-year profit guidances in light of strong quarterly financials released Thursday morning. For AstraZeneca, total revenue increased 17% at ...